These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 2273301

  • 1. [The effect of endogenous tumor necrosis factor (TNF)-induction therapy in the model of VX-2 ovarian carcinoma in the rabbit].
    Hirata S.
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov; 42(11):1477-83. PubMed ID: 2273301
    [Abstract] [Full Text] [Related]

  • 2. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin.
    Satoh M, Inagawa H, Shimada Y, Soma G, Oshima H, Mizuno D.
    J Biol Response Mod; 1987 Oct; 6(5):512-24. PubMed ID: 2445926
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation.
    Mori H, Itoh N, Tamaya T.
    Immunopharmacol Immunotoxicol; 1989 Oct; 11(1):33-53. PubMed ID: 2503555
    [Abstract] [Full Text] [Related]

  • 4. TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF.
    Inagawa H, Oshima H, Soma G, Mizuno D.
    J Biol Response Mod; 1988 Dec; 7(6):596-607. PubMed ID: 3216223
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of liver metastatic ovarian cancer with sequential administration of OK-432 and etoposide].
    Yakabe A, Ito T, Hayashi K, Yamashita S, Ito T, Sugino N.
    Nihon Gan Chiryo Gakkai Shi; 1990 Dec 20; 25(12):2843-7. PubMed ID: 1963633
    [Abstract] [Full Text] [Related]

  • 6. [Changes of cytokine levels in ascitic fluid after intraperitoneal administration of OK-432 or CDDP].
    Terashima M, Takagane A, Abe K, Kuboi M, Asahi H, Saito K.
    Gan To Kagaku Ryoho; 1994 Sep 20; 21(13):2326-9. PubMed ID: 7944471
    [Abstract] [Full Text] [Related]

  • 7. Intratumoral induction of tumour necrosis factor by systemic administration of Bordetella pertussis vaccine.
    Minagawa H, Kobayashi H, Yoshida H, Teranishi M, Morikawa A, Abe S, Oshima H, Mizuno DI.
    Br J Cancer; 1990 Sep 20; 62(3):372-5. PubMed ID: 2206945
    [Abstract] [Full Text] [Related]

  • 8. Endogenous tumor necrosis factor induction with Bordetella pertussis vaccine as a triggering agent and its therapeutic effect on MM46 carcinoma-bearing mice.
    Minagawa H, Kakamu Y, Yoshida H, Tomita F, Oshima H, Mizuno D.
    Jpn J Cancer Res; 1988 Mar 20; 79(3):384-9. PubMed ID: 3131286
    [Abstract] [Full Text] [Related]

  • 9. [Transcatheter arterial embolization with hepatic arterial induction of endogenous TNF in hepatocellular carcinoma].
    Takekoshi H, Oyama R.
    Gan To Kagaku Ryoho; 1989 Aug 20; 16(8 Pt 2):2845-8. PubMed ID: 2476966
    [Abstract] [Full Text] [Related]

  • 10. [Combined effect of cis-DDP (II), OK-432 and systemic hyperthermia in ascites tumor in mice].
    Komatsu K, Nakamura W.
    Nihon Gan Chiryo Gakkai Shi; 1989 Mar 20; 24(3):626-37. PubMed ID: 2504850
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y.
    Immunopharmacol Immunotoxicol; 1988 Mar 20; 10(1):53-65. PubMed ID: 3361071
    [Abstract] [Full Text] [Related]

  • 12. Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432 in vitro, and its augmentation by human interferon gamma.
    Sekimoto M, Kokunai I, Shimano T, Kobayashi T, Takeda T, Haruna N, Yamamoto A, Mori T.
    J Clin Lab Immunol; 1988 Nov 20; 27(3):115-20. PubMed ID: 3150012
    [Abstract] [Full Text] [Related]

  • 13. [Clinical evaluation of intermittent administration of CDDP in advanced ovarian cancer].
    Umesaki N, Kou B, Ooshika Y, Yamamoto K, Sugawa T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb 20; 41(2):191-5. PubMed ID: 2498440
    [Abstract] [Full Text] [Related]

  • 14. [A case report: ovarian carcinoma IVth can become complete remission by immunochemotherapy].
    Shimizu A, Hondoh T, Watanabe S, Moriyama S, Yoshida K, Miyakawa Z, Kimura T, Notake Y, Mitsuya T.
    Gan To Kagaku Ryoho; 1994 Sep 20; 21(13):2346-9. PubMed ID: 7944476
    [Abstract] [Full Text] [Related]

  • 15. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
    Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Noguchi Y.
    Hepatogastroenterology; 2003 Sep 20; 50(54):2259-63. PubMed ID: 14696512
    [Abstract] [Full Text] [Related]

  • 16. Induction of interferon-gamma and tumor necrosis factor in ascites of a patient with ovarian cancer by OK-432.
    Mori H, Itoh N, Shiraki S, Tamaya T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr 20; 40(4):497-8. PubMed ID: 3131464
    [No Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
    Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC.
    Cancer Res; 1993 Apr 15; 53(8):1939-44. PubMed ID: 8385577
    [Abstract] [Full Text] [Related]

  • 18. Radiofrequency ablation and immunostimulant OK-432: combination therapy enhances systemic antitumor immunity for treatment of VX2 lung tumors in rabbits.
    Hamamoto S, Okuma T, Yamamoto A, Kageyama K, Takeshita T, Sakai Y, Nishida N, Matsuoka T, Miki Y.
    Radiology; 2013 May 15; 267(2):405-13. PubMed ID: 23440322
    [Abstract] [Full Text] [Related]

  • 19. Effects of sequential and combined immuno-endocrine therapies using OK-432 (Picibanil) and tamoxifen on the growth of 7,12-dimethylbenz [alpha] anthracene-induced rat mammary carcinoma.
    Iino Y, Yoshida M, Tago T, Owada S, Sugamata N, Horiuchi R.
    Jpn J Clin Oncol; 1991 Feb 15; 21(1):35-8. PubMed ID: 1906118
    [Abstract] [Full Text] [Related]

  • 20. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
    Zagozdzon R, Stokłosa T, Gołab J, Giermasz A, Dabrowska A, Lasek W, Jakóbisiak M.
    Anticancer Res; 1997 Feb 15; 17(6D):4493-8. PubMed ID: 9494557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.